Topadur Pharma

News

8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

Read the full interview:

Download Document Dokument herunterladen Switzerland Global Enterprise Switzerland Global Enterprise

15.10.21

Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

9.11.22

News

Scientific Publication in Pharmaceutics

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

19.5.22

Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607'000 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.